Rodríguez‐Cueto et al. (2018) found that VCE‐003.2 10 mg·kg−1 i.p. successfully improved neuropathological deterioration and normalized CB2 receptor and IL‐1β levels, in an experimental model of amyotrophic lateral sclerosis, but again no mechanisms of action were probed. This evidence concerns the gene IL1B and amyotrophic lateral sclerosis.